EP3763391 - KETONE CARBONYL-CONTAINING HYDROPHOBIC ANTITUMOR DRUG AND CONJUGATE THEREOF AS WELL AS NANO PREPARATION CONTAINING CONJUGATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 11.12.2020 Database last updated on 24.08.2024 | |
Former | The international publication has been made Status updated on 14.09.2019 | Most recent event Tooltip | 26.02.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Jiangsu Jibeier Pharmaceutical Co. Ltd. No.18 Nanwei 2nd Road High-tech Industrial Development Zone Zhenjiang, Jiangsu 212009 / CN | [2021/02] | Inventor(s) | 01 /
YAN, Deyue Room 529, Chemistry Building A No. 800, Dongchuan Road Shanghai 200240 / CN | 02 /
GENG, Zhongyi No. 18, Namwei 2nd Road High-tech Industrial development Zone Zhenjiang, Jiangsu 212009 / CN | 03 /
WANG, Yao Room 535, Chemistry Building A No. 800, Dongchuan Road Shanghai 200240 / CN | 04 /
ZHU, Xinyuan Room 302, Chemistry Building A No. 800, Dongchuan Road Shanghai 200240 / CN | 05 /
HUANG, Wei Room 525, Chemistry Building A No. 800, Dongchuan Road Shanghai 200240 / CN | 06 /
ZHOU, Yongfeng Room 525, Chemistry Building A No. 800, Dongchuan Road Shanghai 200240 / CN | [2021/02] | Representative(s) | Hoeger, Stellrecht & Partner Patentanwälte mbB Uhlandstrasse 14c 70182 Stuttgart / DE | [2021/02] | Application number, filing date | 19764534.4 | 05.03.2019 | [2021/02] | WO2019CN77038 | Priority number, date | CN201810185012 | 06.03.2018 Original published format: CN201810185012 | [2021/02] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019170092 | Date: | 12.09.2019 | Language: | ZH | [2019/37] | Type: | A1 Application with search report | No.: | EP3763391 | Date: | 13.01.2021 | Language: | EN | [2021/02] | Search report(s) | International search report - published on: | CN | 12.09.2019 | (Supplementary) European search report - dispatched on: | EP | 18.05.2022 | Classification | IPC: | A61K47/60, A61K47/54, A61K47/69, A61K31/337, C07D305/14, A61P35/00, A61K31/4745, A61K31/7084, A61K45/06, C07D407/12 | [2022/09] | CPC: |
A61K47/549 (EP);
A61K47/54 (CN);
A61K31/337 (CN,US);
A61K31/4745 (EP);
A61K31/7084 (EP);
A61K45/06 (EP);
A61K47/26 (US);
A61K47/34 (US);
A61K47/60 (EP);
| C-Set: |
A61K31/4745, A61K2300/00 (EP);
A61K31/7084, A61K2300/00 (EP) |
Former IPC [2021/02] | A61K47/60, A61K47/54, A61K47/69, A61K31/337, C07D305/14, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/02] | Title | German: | KETONCARBONYL ENTHALTENDES HYDROPHOBES ANTITUMOR-ARZNEIMITTEL UND KONJUGAT DAVON SOWIE NANOPRÄPARAT MIT DEM KONJUGAT, VERFAHREN ZU SEINER HERSTELLUNG UND SEINE VERWENDUNG | [2021/02] | English: | KETONE CARBONYL-CONTAINING HYDROPHOBIC ANTITUMOR DRUG AND CONJUGATE THEREOF AS WELL AS NANO PREPARATION CONTAINING CONJUGATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | [2021/02] | French: | MÉDICAMENT ANTITUMORAL HYDROPHOBE CONTENANT UN CARBONYLE CÉTONIQUE ET CONJUGUÉ CORRESPONDANT, AINSI QUE PRÉPARATION NANOMÉTRIQUE CONTENANT LE CONJUGUÉ, PROCÉDÉ DE PRÉPARATION ASSOCIÉ, ET APPLICATION ASSOCIÉE | [2021/02] | Entry into regional phase | 14.08.2020 | Translation filed | 14.08.2020 | National basic fee paid | 14.08.2020 | Search fee paid | 14.08.2020 | Designation fee(s) paid | 14.08.2020 | Examination fee paid | Examination procedure | 14.08.2020 | Examination requested [2021/02] | 29.11.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.01.2021 | Renewal fee patent year 03 | 25.01.2022 | Renewal fee patent year 04 | 26.01.2023 | Renewal fee patent year 05 | 26.02.2024 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY]EP2409977 (DAIICHI SANKYO CO LTD [JP]) [X] 13 * compound 102a * [Y] 14,15; | [XAY]CN104857525 (UNIV XIANGTAN) [X] 1,5,8-10,12 * paragraph [0056] * [A] 7 [Y] 3,4,11; | [Y]EP3009516 (GENECHEM INC [KR]) [Y] 1-6,8-12 * figure 13 *; | [XY]WO2016209935 (PLACON THERAPEUTICS INC [US]) [X] 13 * examples 16,17 * [Y] 14,15; | [Y]EP3184540 (YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE& TECH [CN]) [Y] 1-6,8-12 * claim 4 *; | [E]WO2019108975 (CENTURION BIOPHARMA CORP [US]) [E] 13* examples 4,5 *; | [XAY] - FERBER SHIRAN ET AL, "Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome", ELIFE, (20171004), vol. 6, doi:10.7554/eLife.25281, XP055882314 [X] 1,5,6,8-10,12 * figure 1b * [A] 7 [Y] 2-4,11,14,15 DOI: http://dx.doi.org/10.7554/eLife.25281 | [XAY] - VOSSEN LAURA ISABEL ET AL, "PEGylated dendritic polyglycerol conjugate targeting NCAM-expressing neuroblastoma: Limitations and challenges", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, ELSEVIER, AMSTERDAM, NL, (20180220), vol. 14, no. 4, doi:10.1016/J.NANO.2018.02.009, ISSN 1549-9634, pages 1169 - 1179, XP085414597 [X] 1,5,6,8-10,12 * figure 2 * [A] 7 [Y] 2-4,11 DOI: http://dx.doi.org/10.1016/j.nano.2018.02.009 | [XY] - MOU QUANBING ET AL, "A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy", JOURNAL OF CONTROLLED RELEASE, AMSTERDAM, NL, (20160501), vol. 230, doi:10.1016/j.jconrel.2016.03.037, ISSN 0168-3659, pages 34 - 44, XP055882458 [X] 1,4,5,8-10,12 * scheme 1 * [Y] 11 DOI: http://dx.doi.org/10.1016/j.jconrel.2016.03.037 | [X] - ABOU SAMRA ALMA ET AL, "Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, AMSTERDAM, NL, (20180205), vol. 148, doi:10.1016/j.ejmech.2018.01.100, ISSN 0223-5234, pages 26 - 38, XP055919748 [X] 13 * compound 8e * DOI: http://dx.doi.org/10.1016/j.ejmech.2018.01.100 | [X] - MALKI AHMED ET AL, "Synthesis and cytotoxic activity of MOM-ether analogs of isosteviol", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, (20140106), vol. 24, no. 4, doi:10.1016/J.BMCL.2013.12.103, ISSN 0960-894X, pages 1184 - 1187, XP028606687 [X] 13 * compounds 9b, 9d * DOI: http://dx.doi.org/10.1016/j.bmcl.2013.12.103 | [X] - SMITH AMOS B. ET AL, "Design, Synthesis, and Evaluation of Carbamate-Substituted Analogues of (+)-Discodermolide", ORGANIC LETTERS, US, (20050101), vol. 7, no. 2, doi:10.1021/ol047686a, ISSN 1523-7060, pages 311 - 314, XP055919777 [X] 13 * compounds 10,31 * DOI: http://dx.doi.org/10.1021/ol047686a | International search | [X]CN1362956 (UNIV FLORIDA STATE RES FOUND [US]) [X] 20-25 * description, pages 2-4, page 8, paragraph 2 and page 18, paragraph 4 *; | [Y]CN102188717 (UNIV ZHEJIANG) [Y] 1-19 * claim 5 *; | [A]CN104491875 (UNIV CHINA PHARMA) [A] 1-25* entire description *; | [X]CN105031666 (UNIV SHANGHAI JIAOTONG) [X] 1-19 * description, paragraphs [0057]-[0060], figure 12, and claim 10 *; | [Y]CN105031666 (UNIV SHANGHAI JIAOTONG) [Y] 1-19 * description, paragraphs [0057]-[0060], figure 12, and claim 10 *; | [Y]WO2016205738 (CYTRX CORP [US]) [Y] 3, 10 * claim 1 * | by applicant | - Pharmaceutical Research, (19940000), vol. 11, no. 6, pages 889 - 896 | - Journal of Controlled Release, (20050000), vol. 109, no. 1-3, pages 158 - 168 | - Small, (20090000), vol. 5, pages 1706 - 1721 | - Journal of Organic Chemistry, (19950000), vol. 60, no. 2, pages 331 - 336 |